Stockscreener 앱 받기
7.81
0.89%
-0.07
Kamada Ltd 주식(KMDA)의 최신 뉴스
Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance
Kamada Confirms Continuous Global Business Operations and - GlobeNewswire
Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks
Kamada confirms continuous business operations despite Middle East events - TipRanks
Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan
Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -
Implied Volatility Surging for Kamada Stock Options - Yahoo Finance
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent
Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - The Manila Times
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Sidoti Csr Has Optimistic Outlook of Kamada FY2025 Earnings - Defense World
Kamada’s (KMDA) Buy Rating Reiterated at Benchmark - Defense World
Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript - MSN
Is Kamada (KMDA) Stock Undervalued Right Now? - Yahoo Finance
Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade - Yahoo Finance
Kamada Ltd’s Earnings Call Highlights Strong Growth and Expansion - TipRanks
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KM - GuruFocus
Kamada (KMDA) Receives Reiterated Buy Rating from Benchmark | KMDA Stock News - GuruFocus
Benchmark maintains Kamada stock Buy rating with $15 target By Investing.com - Investing.com Nigeria
Kamada: Q1 Earnings Snapshot - CT Insider
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo
Benchmark maintains Kamada stock Buy rating with $15 target - Investing.com
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Kamada Ltd. Reports Strong Q1 2025 Results - TipRanks
Kamada Q1 2025 Earnings Call Transcript - MarketBeat
Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Kamada Reports Strong First Quarter 2025 Financial Results with - GuruFocus
Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations - TipRanks
Kamada Reports Strong First Quarter 2025 Financial Results - GlobeNewswire
Inter Alpha Inhibitor Treatment Market Size in 7MM is expected - openPR.com
Kamada (KMDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Kamada (NASDAQ:KMDA) Upgraded at Sidoti - Defense World
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 - GlobeNewswire
Kamada Ltd. to report Q1 2025 financial results on May 14 - Investing.com Nigeria
Kamada to Release Q1 2025 Financial Results on May 14 - TipRanks
JPMorgan Chase & Co. Invests $67,000 in Kamada Ltd. (NASDAQ:KMDA) - Defense World
Kamada Launches Post-Marketing Research Program for CYTOGAM - TipRanks
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® - GlobeNewswire
Major Breakthrough: Kamada Initiates 10 Clinical Studies to Transform Organ Transplant CMV Treatment - Stock Titan
Geode Capital Management LLC Raises Position in Kamada Ltd. (NASDAQ:KMDA) - Defense World
0.14%
0.27%
자본화:
|
볼륨(24시간):